Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 11/20 | 0.64 |
| ▸ | MAP2K1 | Q02750 | 4/20 | 0.48 |
| ▸ | EGFR | P00533 | 4/20 | 0.43 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1683385 | 0.86 | KDR (0.76) | KDRMAP2K1EGFRERBB2MAPK14 | |
| SCHEMBL1683484 | 0.78 | KDR (1.00) | KDREGFR | |
| SCHEMBL1683487 | 0.78 | KDR (1.00) | KDREGFR | |
| SCHEMBL1226861 | 0.77 | KDR (1.00) | KDREGFRMAPK14 | |
| SCHEMBL1227820 | 0.76 | KDR (0.60) | KDRMAP2K1EGFRERBB2MAPK14 | |
| SCHEMBL1226328 | 0.75 | KDR (0.83) | KDREGFR | |
| SCHEMBL1226906 | 0.73 | KDR (0.82) | KDREGFR | |
| SCHEMBL1683434 | 0.73 | KDR (0.66) | KDRMAP2K1EGFRERBB2MAPK14 | |
| SCHEMBL16716631 | 0.71 | MAP2K1 (0.56) | KDRMAP2K1EGFRERBB2MAPK14 | |
| SCHEMBL4819671 | 0.70 | KDR (0.57) | KDRMAP2K1EGFRERBB2MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539763-B1 | AZAINDOLE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-04-13 | — | — | EP | disclosed |
| US-20060058304-A1 | Azaindole kinase inhibitors | BHIDE RAJEEV S | 2006-03-16 | — | — | US | disclosed |
| US-6969717-B2 | Azaindole kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-11-29 | — | — | US | disclosed |
| US-20040063707-A1 | Azaindole kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063707-A1 | Azaindole kinase inhibitors | FGFR1, FGFR2, FLT1 | KDR 5/4885MAP2K1 633/4885EGFR 43/4885 |
| US-20060058304-A1 | Azaindole kinase inhibitors | FGFR1, FGFR2, FLT1 | KDR 5/4885MAP2K1 570/4885EGFR 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.